Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to determine the benefit of using the FDA-approved insulin-sensitizing agent, Pioglitazone, on human heart transplant recipients. The objectives of this project are to (1) determine if pioglitazone effectively treats insulin resistance in heart transplant recipients, and (2) to determine whether pioglitazone therapy after heart transplantation impacts the development or progression of cardiac allograft vasculopathy (CAV), a form of chronic rejection after heart transplantation.

Clinical Trial Description

CAV, a rapidly progressive obliterative disease involving the graft coronary arteries, is the leading cause of morbidity and mortality beyond the first year after heart transplantation. This common complication occurs in almost half of recipients within 3 years after heart transplantation, and is associated with high rates of graft failure and mortality. Clinical care of heart transplant recipients in the current era is greatly limited by the lack of effective treatment options to prevent or retard the progression of CAV. CAV appears to be strongly associated with the state of insulin resistance, which is present in over half of heart transplant recipients and is characterized by metabolic abnormalities including glucose intolerance, dyslipidemia, endothelial dysfunction, and high levels of circulating inflammatory markers. Insulin resistance can be effectively treated with pioglitazone, a TZD compound which directly affects tissue insulin sensitivity. In this study, we will enroll 32 insulin-resistant heart transplant recipients and will randomize them to pioglitazone or placebo for a one-year period. We will determine the efficacy of pioglitazone for the treatment of insulin resistance and prevention of the development and progression of CAV after heart transplantation. The data generated from this study will provide important preliminary data for future, larger-scale clinical investigations. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01186250
Study type	Interventional
Source	Stanford University
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	July 2010
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02964026` - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients	N/A
Active, not recruiting	`NCT05096299` - OCS Heart EXPAND + CAP Continued Follow-Up
Completed	`NCT02323321` - International EXPAND Heart Pivotal Trial	N/A
Not yet recruiting	`NCT05025774` - Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
Recruiting	`NCT05933083` - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation	N/A
Completed	`NCT03150095` - Health Coaching to Improve Self-Management in Thoracic Transplant Candidates	N/A
Active, not recruiting	`NCT02554578` - Impact of mHealth in Heart Transplant Management	N/A
Terminated	`NCT03346278` - Text Message Intervention to Improve Cardiac Rehab Participation	N/A
Active, not recruiting	`NCT05741723` - OCS DCD Heart + CAP Continued Follow-Up
Completed	`NCT03831048` - Donors After Circulatory Death Heart Trial	N/A
Completed	`NCT04615182` - Donor After Circulatory Death Heart CAP Trial	N/A
Completed	`NCT02597543` - Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction	Phase 4
Recruiting	`NCT05824364` - Exercise aNd hEArt Transplant	N/A
Enrolling by invitation	`NCT05390411` - Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial	N/A
Recruiting	`NCT04770012` - AERIAL Trial: Antiplatelet Therapy in Heart Transplantation	Phase 3
Terminated	`NCT01769443` - Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation	Phase 2
Completed	`NCT00466804` - Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients	N/A
Recruiting	`NCT06426173` - Effect of Resistance Training in Patients on the Waiting List for Heart Transplant	N/A
Not yet recruiting	`NCT05459181` - HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)	N/A
Terminated	`NCT01485757` - Prospective L-arginine Study	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms